Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Karyopharm Therapeutics Inc., Sanofi Genzyme, and Oncopeptides, Inc.
State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches
Release Date: January 15, 2021
Expiration Date: January 15, 2022
Activity Overview
State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches is an online, on-demand virtual symposium, which brings together renowned experts in multiple myeloma (MM). In this educational program, these experts use didactic sessions, panel discussions, and case presentations to discuss the latest advancements in the field of MM. This activity will help health care professionals maintain a state-of-the-art clinical practice by providing updates on novel agents under investigation, recently approved agents, new combination approaches, and optimal sequencing strategies.
This educational activity is an archive of the live virtual symposium held on December 4, 2020.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Karyopharm Therapeutics Inc., Sanofi Genzyme, and Oncopeptides, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward hematologists and hematologists/oncologists interested in the treatment of patients with MM.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement novel therapeutic strategies for patients with relapsed/refractory (R/R) MM based on disease, treatment, and patient-related factors
- Analyze the safety and efficacy data of novel and investigational therapies for the treatment of R/R MM
- Explain the mechanisms of action of novel investigational therapies and the rationale supporting their utility in the treatment of R/R MM
- Apply novel combination approaches to treat R/R MM
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Associate Professor and Consulting Physician
Hematology Department
University Hospital of Salamanca
Salamanca, Spain
Disclosures: Consultant: Janssen Pharmaceutica, Celgene Corporation, Takeda Pharmaceutical Company, Amgen, Adaptive Biotechnologies, AbbVie, Glaxo Smith Kline, Hoffman-La Roche, Seattle Genetics, Pfizer, Regeneron Pharmaceuticals; Speakers Bureau: Janssen Pharmaceutica, Celgene Corporation, Takeda Pharmaceutical Company, Amgen, Adaptive Biotechnologies, AbbVie, GlaxoSmithKline.
Head of the Hematology Department
University Hospital Marqués de Valdecilla
University of Cantabria
Santander, Spain
Disclosures: Consultant: Bristol Myers Squibb, Sanofi, Glaxo Smith Kline, Janssen Pharmaceutica, Amgen, Secura Bio, Oncopeptides; Speakers Bureau: Takeda Pharmaceutical Company, Janssen Pharmaceutica; Other: Honoraria: Janssen Pharmaceutica, Asofarma, Sanofi, Bristol Myers Squibb, Amgen, Merck Sharp & Dohme, Takeda Pharmaceutical Company.
Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Grant Research Support: Janssen Pharmaceutica, Celgene Corporation, Novartis Pharmaceuticals, Amgen, Pharmacyclics, Seattle Genetics, Millenium Pharmaceuticals/Takeda Pharmaceutical Company; Consultant: Janssen Pharmaceutica, Celgene Corporation, Novartis Pharmaceuticals, Amgen, Bristol Myers Squibb, Karyopharm, Sanofi Genzyme, Seattle Genetics, Oncopeptides, Takeda Pharmaceutical Company, Antengene, GlaxoSmithKline, Secura Bio.
Professor of Medicine, Harvard Medical School
Director of the Center for Prevention of Progression
Director of the Clinical Investigator Research Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant: GlaxoSmithKline, Sanofi, Janssen Pharmaceutica, Takeda Pharmaceutical Company, Karyopharm, AbbVie, GNS Healthcare, Genentech, Adaptive Biotechnologies, Bristol Myers Squibb.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.